Journal Watch · Bioinformatics · 2026

Inferring gene expression profiles of tumor clones.

The benchmarking data alongside the intermediate results are available on Zenodo at DOI: 10.5281/zenodo.20446991.

Shafighi S, Jurzysta B, Szczurek EBioinformatics3 min readPharma relevance 30/100

DOI: 10.1093/bioinformatics/btag717PMID: 42830452Study type: genomics / omics study

TL;DR

The benchmarking data alongside the intermediate results are available on Zenodo at DOI: 10.5281/zenodo.20446991.

Key findings

  • Applied to a prostate cancer sample, it reveals clone-specific expression patterns and outperforms its predecessor model in accurately inferring gene expression profiles and explaining spatial transcriptomics signals.
  • Our approach advances the functional and phenotypic characterization of clonal cell subpopulations in tumors.<h4>Availability</h4>The implementation of ClonalGE and the data used in this study can be accessed in the following GitHub repository https://github.com/szczurek-lab/ClonalGE/.
  • The benchmarking data alongside the intermediate results are available on Zenodo at DOI: 10.5281/zenodo.20446991.

What they did

The model proceeds by probabilistic matching of single nucleotide variant sites in spatial transcriptomics to clone-specific variants inferred from DNA sequencing data, and by deconvoluting gene expression in spatial transcriptomics spots into contributions from individual clones. We propose a procedure that utilizes the Monte Carlo posterior samples for identification of differentially expressed genes between clones, using a Highest Density Interval plus Region of Practical Equivalence (HDI+ROPE) criterion that jointly requires credible and practically meaningful effect sizes. ClonalGE demonstrates superior performance on simulated data.

Full abstract (original)

Background: <h4>Motivation</h4>Tumors are heterogeneous mixtures of clonal subpopulations of cells that co-evolve in time and space. Apart from genetic differences, cancer clones may reside in different locations in the tumor tissue and show various transcriptional phenotypes, with specific gene expression profiles and marker genes. Computational tools that simultaneously infer genotypes and transcriptional phenotypes of clones in tumor tissues are lacking.<h4>Results</h4>We introduce ClonalGE, a probabilistic graphical model identifying cancer clone genotypes, their gene expression profiles, and spatial mapping within tumor tissue.

What they did: The model proceeds by probabilistic matching of single nucleotide variant sites in spatial transcriptomics to clone-specific variants inferred from DNA sequencing data, and by deconvoluting gene expression in spatial transcriptomics spots into contributions from individual clones. We propose a procedure that utilizes the Monte Carlo posterior samples for identification of differentially expressed genes between clones, using a Highest Density Interval plus Region of Practical Equivalence (HDI+ROPE) criterion that jointly requires credible and practically meaningful effect sizes. ClonalGE demonstrates superior performance on simulated data.

Results & conclusions: Applied to a prostate cancer sample, it reveals clone-specific expression patterns and outperforms its predecessor model in accurately inferring gene expression profiles and explaining spatial transcriptomics signals. Our approach advances the functional and phenotypic characterization of clonal cell subpopulations in tumors.<h4>Availability</h4>The implementation of ClonalGE and the data used in this study can be accessed in the following GitHub repository https://github.com/szczurek-lab/ClonalGE/. The benchmarking data alongside the intermediate results are available on Zenodo at DOI: 10.5281/zenodo.20446991.

Abstract © the authors / Bioinformatics (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1093/bioinformatics/btag717 · PubMed 42830452.

Why it matters for pharma & biotech

  • Relevant to Biotechnology & Methods teams tracking Bioinformatics for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Bioinformatics study find?

The benchmarking data alongside the intermediate results are available on Zenodo at DOI: 10.5281/zenodo.20446991.

What type of study is this?

It is a genomics / omics study, published in Bioinformatics in 2026. The model proceeds by probabilistic matching of single nucleotide variant sites in spatial transcriptomics to clone-specific variants inferred from DNA sequencing data, and by deconvoluting gene expression in spatial transcriptomics spots into contributions from individual clones.

Where can I read the original paper?

The original is at the publisher via DOI 10.1093/bioinformatics/btag717. PubMed ID: 42830452. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Shafighi S, Jurzysta B, Szczurek E. Inferring gene expression profiles of tumor clones.. Bioinformatics (2026). DOI: 10.1093/bioinformatics/btag717.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/inferring-gene-expression-profiles-of-tumor-clones-tag717/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides